JPH0480007B2 - - Google Patents
Info
- Publication number
- JPH0480007B2 JPH0480007B2 JP23776487A JP23776487A JPH0480007B2 JP H0480007 B2 JPH0480007 B2 JP H0480007B2 JP 23776487 A JP23776487 A JP 23776487A JP 23776487 A JP23776487 A JP 23776487A JP H0480007 B2 JPH0480007 B2 JP H0480007B2
- Authority
- JP
- Japan
- Prior art keywords
- soysterol
- pantethine
- present
- group
- hyperlipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 19
- 229960000903 pantethine Drugs 0.000 claims description 19
- 235000008975 pantethine Nutrition 0.000 claims description 19
- 239000011581 pantethine Substances 0.000 claims description 19
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 19
- 229940033331 soy sterol Drugs 0.000 claims description 19
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 13
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 11
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 229930003427 Vitamin E Natural products 0.000 description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 10
- 229940046009 vitamin E Drugs 0.000 description 10
- 239000011709 vitamin E Substances 0.000 description 10
- 235000019165 vitamin E Nutrition 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- 150000003789 δ-tocopherols Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23776487A JPS6479119A (en) | 1987-09-22 | 1987-09-22 | Drug of blended two components |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23776487A JPS6479119A (en) | 1987-09-22 | 1987-09-22 | Drug of blended two components |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6479119A JPS6479119A (en) | 1989-03-24 |
| JPH0480007B2 true JPH0480007B2 (es) | 1992-12-17 |
Family
ID=17020100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23776487A Granted JPS6479119A (en) | 1987-09-22 | 1987-09-22 | Drug of blended two components |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6479119A (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1721C2 (ro) * | 1994-09-29 | 2002-01-31 | The University Of British Columbia | Procedeu de separare a compoziţiei de fitosteroli din săpun de pulpă, compoziţie de reducere a nivelului de colesterol şi produs terapeutic |
| CA2501021C (en) * | 2002-09-30 | 2011-02-22 | Daiichi Pharmaceutical Co., Ltd. | Pantethine-containing particulate |
| JP2006016356A (ja) * | 2004-07-02 | 2006-01-19 | Dai Ichi Seiyaku Co Ltd | 高コレステロール症用組成物 |
-
1987
- 1987-09-22 JP JP23776487A patent/JPS6479119A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6479119A (en) | 1989-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL193340C (nl) | Farmaceutisch preparaat voor parenterale toediening gevormd uit een vetemulsie. | |
| US5173304A (en) | Agents for the treatment of severe pain and preparation of said agents | |
| JPH06501695A (ja) | 主要血管事象を抑制するためのベータ−カロテン及びビタミンｅ療法 | |
| US20060166959A1 (en) | Pharmaceutical compositions based on azetidine derivatives | |
| JP2002518440A (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法 | |
| KR100272483B1 (ko) | 지질 대사 개선제 | |
| US11839590B2 (en) | Flurbiprofen axetil emulsion for injection and preparation method thereof | |
| EP0759294B1 (en) | Hypercholesterolemia therapeutic agent | |
| JP5021887B2 (ja) | アゼチジン誘導体に基づく医薬組成物 | |
| Rasker et al. | Lack of beneficial effect of zinc sulphate in rheumatoid arthritis | |
| EP0891771A1 (en) | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases | |
| AU2018352039A1 (en) | Cannabidiol and chitosan compositions and methods of using the same | |
| EP0629405A1 (en) | Agent for inhibiting a decrease in bone mass in renal osteodystrophy | |
| JP2002249431A (ja) | トリグリセリド低下剤組成物 | |
| JPH0480007B2 (es) | ||
| US4472436A (en) | Increasing HDL-cholesterol levels with phenylethylamine derivatives | |
| JP2003277281A (ja) | 静脈炎の予防及び治療のための医薬 | |
| AU2004290925B2 (en) | Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients | |
| JP2000038352A (ja) | 外用組成物 | |
| AU611204B2 (en) | Treatment of lipoprotein disorders associated with cholesterol metabolism | |
| CA2207943A1 (en) | Therapeutic agent for joint diseases | |
| ES2236487T3 (es) | Formulacion farmaceutica y su uso para preparar un medicamento para el tratamiento de enfermedades cardiovasculares. | |
| KR20210148078A (ko) | 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물 | |
| JPH08208464A (ja) | 高脂血症の治療及び予防薬 | |
| JPH06298645A (ja) | 高脂血症治療・予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071217 Year of fee payment: 15 |